Saturday 17 October 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
16.20
2.59
−13.78%
Follow OMER
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (89.15%) | (62.24%) | 2.21% | 64.68% |
+8 more TTM periods Free account |
|
| 51.22% | 33.06% | (1.11%) | (48.56%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
136.19% | 70.38% | (2.40%) | 1,745.30% | |
Average Days of Receivables |
79.95 | 48.92 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.95) | (1.32) | (1.83) | (1.59) | |
Free Cash Flow |
(68.74) | (94.76) | (116.16) | (105.32) | |
Capital Expenditures |
(0.07) | — | (0.06) | (0.09) | |
| Other line items | |||||
Cash ROIC |
(38.65%) | (45.38%) | (42.06%) | 1,349.95% | |
Accounts Receivable Turnover |
7.05 | 9.40 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.25 | 0.26 | 0.00 | 0.00 | |
Inventory Turnover |
1.85 | 1.65 | — | — | |
Average Days of Payables |
1,229.79 | 1,542.48 | 0.00 | 0.00 | |
Days of Inventory on Hand |
163.30 | 52.59 | — | — | |
Tax Rate |
0.20 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
64.37% | 78.87% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
48.60% | 48.73% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
7.39% | 8.50% | 0.00% | 0.00% | |
Interest Coverage |
(8.23) | (82.22) | 127.91 | 19.52 | |
Operating CF/Net income |
(0.55) | (1.10) | 34.65 | 0.87 | |
Depreciation/Fixed assets |
3.19 | 0.18 | (0.38) | (3.11) | |
Capex/Depreciation |
(0.02) | 0.00 | 0.10 | 0.01 | |
Revenue per Share |
1.35 | 1.25 | 0.00 | 0.00 | |
Operating CF per Share |
(0.95) | (1.32) | (1.83) | (1.59) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates